Eli Lilly and Company (NYSE:LLY) Stock Falls 1.6% – Here’s Why

Eli Lilly and Company (NYSE:LLY)’s stock price fell 1.6% during mid-day trading on Thursday. The company traded as low as $1,131.21 and last traded at $1,169.7650. 3,074,844 shares changed hands during trading, an increase of 3% from the average daily volume of 2,974,658 shares. The stock had previously closed at $1,188.72.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,440 and reiterated an “overweight” rating, implying substantial upside from recent levels. The call reflects confidence in Lilly’s earnings growth and pipeline. Cantor Fitzgerald price-target report
• Positive Sentiment: Analysts and investors continue to highlight Lilly’s growth beyond Mounjaro and Zepbound. Retatrutide, a next-generation obesity candidate, has produced greater weight loss in trials and could be filed with regulators in early 2027. The broader obesity platform may also address fatty liver disease, sleep apnea and other conditions. Lilly obesity pipeline article
• Positive Sentiment: New or expanding clinical studies for eloralintide, Alzheimer’s treatments and Lilly’s oncology portfolio provide additional long-term catalysts. Jaypirca, Inluriyo and Retevmo could help offset slower growth from mature products. Lilly pipeline update
• Neutral Sentiment: Technical commentary identifies the 50-day moving average as an important support level and describes a move above it as a potential short-term bullish signal. However, technical support has not resolved the stock’s valuation concerns. Lilly moving-average analysis
• Negative Sentiment: Investors remain concerned that Lilly trades at a premium multiple after its powerful GLP-1 rally. Competition, future pricing pressure and the long regulatory timeline for next-generation drugs could limit near-term upside.
• Negative Sentiment: Early-stage trial announcements for eloralintide and Alzheimer’s therapies do not yet provide efficacy or approval evidence, so they offer limited immediate earnings support. The market is also awaiting further proof that pipeline products can sustain growth as current blockbusters mature.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a “buy” rating in a report on Thursday, September 17th. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. Sanford C. Bernstein increased their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Bank of America lifted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,313.43.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The company has a fifty day moving average price of $1,173.51 and a 200 day moving average price of $1,094.59. The stock has a market cap of $1.10 trillion, a P/E ratio of 39.25, a P/E/G ratio of 1.42 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter last year, the firm posted $6.31 EPS. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts expect that Eli Lilly and Company will post 36.66 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds have recently modified their holdings of the company. Aletheian Wealth Advisors LLC boosted its position in Eli Lilly and Company by 1.8% in the third quarter. Aletheian Wealth Advisors LLC now owns 1,039 shares of the company’s stock worth $1,202,000 after purchasing an additional 18 shares during the last quarter. YHB Investment Advisors Inc. grew its stake in Eli Lilly and Company by 4.8% in the 3rd quarter. YHB Investment Advisors Inc. now owns 9,940 shares of the company’s stock valued at $11,501,000 after buying an additional 452 shares in the last quarter. Titleist Asset Management LLC raised its stake in shares of Eli Lilly and Company by 13.7% during the 3rd quarter. Titleist Asset Management LLC now owns 1,027 shares of the company’s stock valued at $1,188,000 after purchasing an additional 124 shares during the period. Apella Capital LLC increased its position in shares of Eli Lilly and Company by 58.4% during the third quarter. Apella Capital LLC now owns 6,774 shares of the company’s stock valued at $8,053,000 after buying an additional 2,498 shares during the period. Finally, Everhart Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 3.5% in the third quarter. Everhart Financial Group Inc. now owns 8,273 shares of the company’s stock worth $9,572,000 after buying an additional 283 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.